To test this hypothesis, we constructed ESCC cells with targeted Ezrin knockdown, and studied the specific molecular mechanism by which Ezrin promotes ESCC malignant progression at the cellular and molecular levels, as well as the interaction between Ezrin and YAP1 in ESCC occurrence and development, providing new targets for the clinical prevention or treatment of ESCC. This evidence concerns the gene YAP1 and esophageal squamous cell carcinoma.